At the time of writing, Xeris Biopharma Holdings Inc [XERS] stock is trading at $2.05, down -1.44%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The XERS shares have gain 0.49% over the last week, with a monthly amount drifted -33.44%, and not seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
On 3, April 2024, Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4). In a post published today on Yahoo Finance, Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced that on April 1, 2024, the Compensation Committee of Xeris’ Board of Directors granted restricted stock units for an aggregate of 103,000 shares of its common stock to 18 new employee(s) under Xeris’ Inducement Equity Plan.
From an analyst’s perspective:
Xeris Biopharma Holdings Inc [NASDAQ: XERS] stock has seen the most recent analyst activity on March 28, 2024, when Oppenheimer initiated its Outperform rating and assigned the stock a price target of $5. Previously, Craig Hallum started tracking the stock with Buy rating on August 28, 2023, and set its price target to $4.50. On October 21, 2022, Jefferies initiated with a Buy rating and assigned a price target of $4 on the stock. Craig Hallum started tracking the stock assigning a Buy rating and suggested a price target of $6.50 on April 28, 2022. SVB Leerink initiated its recommendation with a Outperform and recommended $6 as its price target on November 17, 2021. H.C. Wainwright started tracking with a Buy rating for this stock on October 29, 2021, and assigned it a price target of $4.
For the past year, the stock price of Xeris Biopharma Holdings Inc fluctuated between $1.46 and $3.26. Currently, Wall Street analysts expect the stock to reach $6.5 within the next 12 months. Xeris Biopharma Holdings Inc [NASDAQ: XERS] shares were valued at $2.05 at the most recent close of the market. An investor can expect a potential return of 217.07% based on the average XERS price forecast.
Analyzing the XERS fundamentals
According to Xeris Biopharma Holdings Inc [NASDAQ:XERS], the company’s sales were 163.91M for trailing twelve months, which represents an 33.93% jump. Gross Profit Margin for this corporation currently stands at 0.81% with Operating Profit Margin at -0.27%, Pretax Profit Margin comes in at -0.39%, and Net Profit Margin reading is -0.38%. To continue investigating profitability, this company’s Return on Assets is posted at -0.18, Equity is -6.11 and Total Capital is -0.18. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of-28.67.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 2.01 points at the first support level, and at 1.97 for the second support level. However, for the 1st resistance point, the stock is sitting at 2.10, and for the 2nd resistance point, it is at 2.15.
Xeris Biopharma Holdings Inc [XERS] reported earnings per share of -$0.1 for its fiscal quarter that ended on 12/30/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$0.1/share, meaning a difference of $0 and a surprise factor of 0.00%. By comparison, the stated earnings for the previous quarter ended on 9/29/2023 were -$0.09 per share as compared to estimates of -$0.12 per share, a difference of $0.03 representing a surprise of 25.00%.
Ratios To Look Out For
It is important to note that Xeris Biopharma Holdings Inc [NASDAQ:XERS] has a current ratio of 1.64. Further, the Quick Ratio stands at 1.23, while the Cash Ratio is 0.71. Considering the valuation of this stock, the price to sales ratio is 1.76.
Transactions by insiders
Recent insider trading involved Schmid John P., Director, that happened on Mar 14 ’24 when 4500.0 shares were purchased. Director, SHERMAN JEFFREY W completed a deal on Nov 27 ’23 to buy 5400.0 shares. Meanwhile, Pieper Steven bought 28000.0 shares on Nov 20 ’23.
